Abnormal skeletal metabolism and its changes after decopper therapy in patients with Wilson disease

作     者：Guang'e Yang Minfan Hong Bin Yang Renmin Yang Xun Wang 

作者机构：Department of NeurologyAffiliated Hospital of Institute of Neurology Anhui College of Traditional Chinese MedicineHefei 230061Anhui ProvinceChina Department of NeurologyAffiliated Hospital of Institute of Neurology Anhui College of Traditional Chinese MedicineHefei 230061Anhui ProvinceChina Department of NeurologyAffiliated Hospital of Institute of Neurology Anhui College of Traditional Chinese MedicineHefei 230061Anhui ProvinceChina Department of NeurologyAffiliated Hospital of Institute of Neurology Anhui College of Traditional Chinese MedicineHefei 230061Anhui ProvinceChina Department of NeurologyAffiliated Hospital of Institute of Neurology Anhui College of Traditional Chinese MedicineHefei 230061Anhui ProvinceChina 

出 版 物：《Neural Regeneration Research》 (中国神经再生研究（英文版）)

年 卷 期：2006年第1卷第7期

页      面：626-629页

核心收录：

学科分类：1002[医学-临床医学] 100204[医学-神经病学] 10[医学] 

主　　题：Wilson Abnormal skeletal metabolism and its changes after decopper therapy in patients with Wilson disease 

摘      要：BACKGROUND: Researches indicate that patients with Wilson disease (WD) have abnormal skeletal metabolism, which is induced by various factors. OBJECTIVE: To probe into the changing characteristics of abnormal skeletal metabolism in WD patients and observe the effect of decopper therapy. DESIGN: Case-contrast and self-control study. SETTING: Department of Neurology, Affiliated Hospital of Neurological Institute, Anhui College of Traditional Chinese Medicine. PARTICIPANTS: A total of 35 patients with WD including 21 males and 14 females aged from 10 to 42 years with the mean age of (20±8) years were selected from Department of Neurology, Affiliated Hospital of Neurological Institute, Anhui College of Traditional Chinese Medicine from September 2000 to February 2001. All the patients were in compliance with the diagnostic criteria: history of family heredity; cone symptoms in vitro, physical sign or liver symptoms; positive Kayser-Fleischer ring; serum copper protein 1.6 μmol/24 hours; liver copper 250 μg/g (dry weight). The control group was selected from 25 cases of health individuals including 13 males and 12 females aged from 16 to 35 years with the mean age of (22±6) years. All patients who participated in the study were informed first and consented. METHODS: Patients in treatment group were treated with venous injection of 1.0 g sodium dimercaptosulfonate, once a day for totally 6 successive days. And then, patients rested for 2 days. This procedure mentioned above was regarded as a course, and the treatment lasted for 4-8 courses. Before and after injection of sodium dimercaptosulfonate, serum calcitonin (CT), osteocalcin (BGP), parathyroid hormone (PTH) and 1,25-(OH)2VitD3 were measured with radio-immunity method; blood, urine calcium, phosphorum and urine creatinine were measured with biochemical analyzer; urine dihydropyrimidine dehydrogenase(DPD) was detected with enzyme-immunity method; bone mineral den